These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 1954007)

  • 1. EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Jul; 19(3):247-51. PubMed ID: 1954007
    [No Abstract]   [Full Text] [Related]  

  • 2. Note for guidance. Guidelines for medicinal products derived from human blood and plasma. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1992 Jun; 20(2):159-64. PubMed ID: 1389112
    [No Abstract]   [Full Text] [Related]  

  • 3. Note for guidance. Production and quality control of human monoclonal antibodies. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Apr; 19(2):133-8. PubMed ID: 1888492
    [No Abstract]   [Full Text] [Related]  

  • 4. Note for guidance. Guidelines for minimizing the risk of transmitting agents causing spongiform encephalopathy via medicinal products. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1992 Jun; 20(2):155-8. PubMed ID: 1389111
    [No Abstract]   [Full Text] [Related]  

  • 5. Virus validation procedures: practical aspects.
    Minor PD
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S10-2. PubMed ID: 7495959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Note for guidance. Production and quality control of cytokine products derived by biotechnological processes. Committee for Proprietary Medicinal Products: Ad hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Apr; 19(2):125-31. PubMed ID: 1888491
    [No Abstract]   [Full Text] [Related]  

  • 7. European project concerning the guidelines on medicinal products derived from human blood and plasma.
    Horaud F
    Dev Biol Stand; 1991; 75():237-40. PubMed ID: 1794627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
    Celis P; Silvester G
    Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Viral safety: European and French directives].
    Rossi F; Legras JF
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S55-61. PubMed ID: 10896992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of bacteriophages as surrogates for mammalian viruses.
    McAlister M; Aranha H; Larson R
    Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theoretical considerations on viral inactivation or elimination.
    Willkommen H; Löwer J
    Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
    [No Abstract]   [Full Text] [Related]  

  • 12. Virological issues in the use of cell therapies.
    Minor PD
    Dev Biol (Basel); 2004; 118():151-3. PubMed ID: 15645685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of virus removal and inactivation procedures. Ad hoc Working Party on Biotechnology/Pharmacy.
    Pharmacol Toxicol; 1991 Aug; 69(2):144-8. PubMed ID: 1775434
    [No Abstract]   [Full Text] [Related]  

  • 14. Animal virus contaminants of biotechnology products.
    Onions D
    Dev Biol (Basel); 2004; 118():155-63. PubMed ID: 15645686
    [No Abstract]   [Full Text] [Related]  

  • 15. Qualification of virus/cell systems for their intended use.
    Gröner A
    Dev Biol (Basel); 2004; 118():55-63. PubMed ID: 15645673
    [No Abstract]   [Full Text] [Related]  

  • 16. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider.
    Vicari G
    Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral safety of a new highly purified factor VIII (OCTATE).
    Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
    J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Criteria for the choice of viruses in validation studies.
    Minor PD
    Dev Biol Stand; 1993; 81():215-9. PubMed ID: 8174805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations in performing virus spiking experiments and process validation studies.
    Darling AJ
    Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.